Editorial: Model organisms in respiratory pharmacology 2023.
作者信息
McCarron Alexandra, Surolia Ranu, Ruffini Livia
机构信息
Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.
Department of Respiratory and Sleep Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
出版信息
Front Pharmacol. 2025 Jan 13;15:1540222. doi: 10.3389/fphar.2024.1540222. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Model organisms in respiratory pharmacology 2023.社论：2023年呼吸药理学中的模式生物
Front Pharmacol. 2025 Jan 13;15:1540222. doi: 10.3389/fphar.2024.1540222. eCollection 2024.
2
Editorial overview: Respiratory: Pulmonary pharmacology-The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives.社论概述：呼吸领域：肺部药理学——肺部医学新疗法的出现终于带来了切实的治疗前景。
Curr Opin Pharmacol. 2021 Oct;60:54-58. doi: 10.1016/j.coph.2021.07.001. Epub 2021 Aug 2.
3
Editorial: Evolution in respiratory pharmacology.社论：呼吸药理学的发展
Front Pharmacol. 2023 Nov 17;14:1329811. doi: 10.3389/fphar.2023.1329811. eCollection 2023.
4
ELIMINATION OF PLEUROPNEUMONIA-LIKE ORGANISMS FROM EMBRYONIC HUMAN LUNG TISSUE CULTURE WITH TETRACYCLINE.用四环素从人胚胎肺组织培养物中清除类胸膜肺炎微生物。
J Bacteriol. 1964 Jan;87(1):237. doi: 10.1128/jb.87.1.237-237.1964.
5
Computational pharmacokinetics at a crossroads.处于十字路口的计算药代动力学。
In Silico Pharmacol. 2013 Mar 6;1:5. doi: 10.1186/2193-9616-1-5. eCollection 2013.
6
Editorial: Model organisms in experimental pharmacology and drug discovery 2023: rodent, worm and zebrafish models.社论：2023年实验药理学与药物发现中的模式生物：啮齿动物、蠕虫和斑马鱼模型
Front Pharmacol. 2024 Aug 8;15:1462972. doi: 10.3389/fphar.2024.1462972. eCollection 2024.
7
Editorial: Methods in respiratory pharmacology 2023.社论：2023年呼吸药理学方法
Front Pharmacol. 2025 Jan 14;16:1527053. doi: 10.3389/fphar.2025.1527053. eCollection 2025.
8
Editorial: Model organisms in experimental pharmacology and drug discovery 2022.社论：2022年实验药理学与药物发现中的模式生物
Front Pharmacol. 2023 Mar 29;14:1143934. doi: 10.3389/fphar.2023.1143934. eCollection 2023.
9
Editorial: Computational and Experimental Approaches in Multi-target Pharmacology.社论：多靶点药理学中的计算与实验方法
Front Pharmacol. 2017 Jun 30;8:443. doi: 10.3389/fphar.2017.00443. eCollection 2017.
10
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.定量系统药理学建模和机器学习在心力衰竭中的应用及挑战综述。
J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):39-50. doi: 10.1007/s10928-021-09785-6. Epub 2021 Oct 12.
引用本文的文献
1
Curcumin-loaded nanoemulsion for acute lung injury treatment nebulization: Formulation, optimization and studies.用于急性肺损伤治疗雾化的姜黄素纳米乳剂：制剂、优化及研究
ADMET DMPK. 2025 Mar 20;13(2):2661. doi: 10.5599/admet.2661. eCollection 2025.
本文引用的文献
1
Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019.1990 - 2019年慢性呼吸道疾病及其风险因素的全球负担：全球疾病负担研究2019年的最新情况
EClinicalMedicine. 2023 May;59:101936. doi: 10.1016/j.eclinm.2023.101936.
2
Computational lung modelling in respiratory medicine.计算呼吸医学中的肺部建模。
J R Soc Interface. 2022 Jun;19(191):20220062. doi: 10.1098/rsif.2022.0062. Epub 2022 Jun 8.
3
Extracellular histones in lung dysfunction: a new biomarker and therapeutic target?细胞外组蛋白与肺功能障碍：一种新的生物标志物和治疗靶点？
Pulm Circ. 2020 Nov 10;10(4):2045894020965357. doi: 10.1177/2045894020965357. eCollection 2020 Oct-Dec.
4
Cell and animal models of SARS-CoV-2 pathogenesis and immunity.SARS-CoV-2 发病机制和免疫的细胞和动物模型。
Dis Model Mech. 2020 Sep 1;13(9):dmm046581. doi: 10.1242/dmm.046581.
5
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.CFTR调节剂：精准医学时代囊性纤维化的新面貌
Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.
6
Phenotypic Characterization and Comparison of Cystic Fibrosis Rat Models Generated Using CRISPR/Cas9 Gene Editing.使用 CRISPR/Cas9 基因编辑技术生成的囊性纤维化大鼠模型的表型特征分析及比较。
Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.
7
Cystic Fibrosis Lung Disease: An Overview.囊性纤维化肺病：概述。
Respir Care. 2020 Feb;65(2):233-251. doi: 10.4187/respcare.06697. Epub 2019 Nov 26.
8
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
9
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
10
Improving the quality of life of people with advanced respiratory disease and severe breathlessness.改善晚期呼吸系统疾病和严重呼吸困难患者的生活质量。
Breathe (Sheff). 2019 Sep;15(3):198-215. doi: 10.1183/20734735.0200-2019.
Zotero 插件